All Stories

  1. Clinical Proteomics in Cardiovascular Medicine: Current Capabilities, Limitations, and Future Directions
  2. Anti‐Malondialdehyde Low‐Density Lipoprotein Antibodies and Valvular Calcification: A Substudy of the SCOT‐HEART Trial
  3. A genetic map of human metabolism across the allele frequency spectrum
  4. Precision medicine requires precision proteomics: Discordance between proteomic and clinical assays in UK Biobank
  5. Cardiac regeneration beyond stem cells: harnessing sarcomere dynamics and endogenous repair mechanisms
  6. Platelets and inflammation—insights from platelet non-coding RNA content and release in the Bruneck study and the PACMAN-AMI trial
  7. ECM Modifications Driven by Age and Metabolic Stress Directly Promote Vascular Smooth Muscle Cell Osteogenic Processes
  8. Transcriptional Atlas of Cardiac Disease
  9. A genetic map of human metabolism across the allele frequency spectrum
  10. Cervical Artery Tortuosity Is Associated With Dissection Occurrence and Late Recurrence: A Nested Case-Control Study
  11. Dissecting the effect of genetic variants on atherosclerosis: integrating bulk and single-cell transcriptomics
  12. Differential effects of physiological agonists on the proteome of platelet‐derived extracellular vesicles
  13. Longitudinal Lipidomic Signature of Coronary Heart Disease in American Indian People
  14. Enhancing cardiovascular risk prediction through proteomics?
  15. Inhibition of miR-199a-3p in a murine hypertrophic cardiomyopathy (HCM) model attenuates fibrotic remodeling
  16. Phenylalanine-tRNA aminoacylation is compromised by ALS/FTD-associated C9orf72 C4G2 repeat RNA
  17. Proteomic Atlas of Atherosclerosis: The Contribution of Proteoglycans to Sex Differences, Plaque Phenotypes, and Outcomes
  18. Human blood vessel organoids reveal a critical role for CTGF in maintaining microvascular integrity
  19. Effect of Alirocumab Added to High-Intensity Statin on Platelet Reactivity and Noncoding RNAs in Patients with AMI: A Substudy of the PACMAN-AMI Trial
  20. SERCA2a Protein Levels Are Unaltered in Human Heart Failure
  21. Cross-Linking Mass Spectrometry Uncovers Interactions Between High-Density Lipoproteins and the SARS-CoV-2 Spike Glycoprotein
  22. Uncovering Protein Networks in Cardiovascular Proteomics
  23. Reducing reductionism: addressing risk for atherosclerotic cardiovascular disease by apolipoprotein proteomics
  24. Proteomics and lipidomics in atherosclerotic cardiovascular disease risk prediction
  25. Desmosomal protein degradation as an underlying cause of arrhythmogenic cardiomyopathy
  26. Apolipoprotein Proteomics for Residual Lipid-Related Risk in Coronary Heart Disease
  27. CNP Promotes Antiarrhythmic Effects via Phosphodiesterase 2
  28. Letter by Gutmann et al Regarding Article, “Circulating MicroRNA-122-5p Is Associated With a Lack of Improvement in Left Ventricular Function After Transcatheter Aortic Valve Replacement and Regulates Viability of Cardiomyocytes Through Extracellular V...
  29. Extracellular Matrix Profiling and Disease Modelling in Engineered Vascular Smooth Muscle Cell Tissues
  30. Temporal in vivo platelet labeling in mice reveals age-dependent receptor expression and conservation of specific mRNAs
  31. Reduced secretion of neuronal growth regulator 1 contributes to impaired adipose-neuronal crosstalk in obesity
  32. Vascular smooth muscle cell senescence accelerates medin aggregation via small extracellular vesicle secretion and extracellular matrix reorganization
  33. SGLT2 inhibitors in heart failure: insights from plasma proteomics
  34. Phenylalanine-tRNA aminoacylation is compromised by ALS/FTD-associated C9orf72 C4G2 repeat RNA
  35. Integrative single-cell meta-analysis reveals disease-relevant vascular cell states and markers in human atherosclerosis
  36. SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
  37. Human blood vessel organoids reveal a critical role for CTGF in maintaining microvascular integrity
  38. Serial measurements of protein and microRNA biomarkers to specify myocardial infarction subtypes
  39. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction
  40. Precision Medicine Approach for Cardiometabolic Risk Factors in Therapeutic Apheresis
  41. Correction: Precision Medicine Approach for Cardiometabolic Risk Factors in Therapeutic Apheresis
  42. Methods for the identification and characterization of extracellular vesicles in cardiovascular studies: from exosomes to microvesicles
  43. Circulating microRNAs as biomarkers and mediators of platelet activation
  44. Sexual dimorphism in COVID-19: potential clinical and public health implications
  45. Linking Genetics and Proteomics: Gene-Protein Associations Built on Diversity
  46. Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC Working Group on Myocardial Function and the ESC Working Group on Cellular Biology of the Heart
  47. Association of adolescent lipoprotein subclass profile with carotid intima-media thickness and comparison to adults: Prospective population-based cohort studies
  48. Isolation of Circulating Extracellular Vesicles by High-Performance Size-Exclusion Chromatography
  49. Neutrophil-Derived Protein S100A8/A9 Alters the Platelet Proteome in Acute Myocardial Infarction and Is Associated With Changes in Platelet Reactivity
  50. Extracellular Matrix in Heart Failure: Role of ADAMTS5 in Proteoglycan Remodeling
  51. Temporal in vivo platelet labelling in mice reveals age-dependent receptor expression and conservation of specific mRNAs
  52. Proteome and functional decline as platelets age in the circulation
  53. PCSK9 Activity Is Potentiated Through HDL Binding
  54. Association of cardiometabolic microRNAs with COVID-19 severity and mortality
  55. Protein Aggregation Is an Early Manifestation of Phospholamban p.(Arg14del)–Related Cardiomyopathy: Development of PLN-R14del–Related Cardiomyopathy
  56. Diminished PLK2 Induces Cardiac Fibrosis and Promotes Atrial Fibrillation
  57. Endothelial cells exposed to atheroprotective flow secrete follistatin-like 1 protein which reduces transcytosis and inflammation
  58. DRP1: a novel regulator of PCSK9 secretion and degradation
  59. Lessons from the spatiotemporal expression patterns of RNA vs. proteins during the cell cycle
  60. SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care
  61. Proteome and functional decline as platelets age in the circulation
  62. Lipoprotein compartmentalisation as a regulator of PCSK9 activity
  63. The Landscape of Coding and Noncoding RNAs in Platelets
  64. Impairment of the ER/mitochondria compartment in human cardiomyocytes with PLN p.Arg14del mutation
  65. Fibroblast GATA-4 and GATA-6 promote myocardial adaptation to pressure overload by enhancing cardiac angiogenesis
  66. The transCampus Metabolic Training Programme Explores the Link of SARS-CoV-2 Virus to Metabolic Disease
  67. Fibroblast Nox2 (NADPH Oxidase-2) Regulates ANG II (Angiotensin II)–Induced Vascular Remodeling and Hypertension via Paracrine Signaling to Vascular Smooth Muscle Cells
  68. Loss of hepatic miR-33 improves metabolic homeostasis and liver function without altering body weight or atherosclerosis
  69. A Proteomics-Based Assessment of Inflammation Signatures in Endotoxemia
  70. Systems biology in cardiovascular disease: a multiomics approach
  71. SARS-CoV-2 RNAemia and proteomic biomarker trajectory inform prognostication in COVID-19 patients admitted to intensive care
  72. Proteomic landscape of TGF-β1-induced fibrogenesis in renal fibroblasts
  73. Paracrine signalling by cardiac calcitonin controls atrial fibrogenesis and arrhythmia
  74. Metabolic recovery after weight loss surgery is reflected in serum microRNAs
  75. Extracellular matrix protein signature of recurrent spontaneous cervical artery dissection
  76. Cathepsin A contributes to left ventricular remodeling by degrading extracellular superoxide dismutase in mice
  77. Right Ventricle Has Normal Myofilament Function But Shows Perturbations in the Expression of Extracellular Matrix Genes in Patients With Tetralogy of Fallot Undergoing Pulmonary Valve Replacement
  78. Platelet “-omics” in health and cardiovascular disease
  79. Very preterm birth results in later lower platelet activation markers
  80. Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs: novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart
  81. Platelet Reactivity in Individuals Over 65 Years Old Is Not Modulated by Age
  82. Noncoding RNAs versus Protein Biomarkers in Cardiovascular Disease
  83. microRNAs as Promising Biomarkers of Platelet Activity in Antiplatelet Therapy Monitoring
  84. Towards standardization of echocardiography for the evaluation of left ventricular function in adult rodents: a position paper of the ESC Working Group on Myocardial Function
  85. Extracellular Matrix in Vascular Disease, Part 2/4
  86. Circulating MicroRNA Levels Indicate Platelet and Leukocyte Activation in Endotoxemia Despite Platelet P2Y12 Inhibition
  87. Pkm2 Regulates Cardiomyocyte Cell Cycle and Promotes Cardiac Regeneration
  88. The ‘Digital Twin’ to enable the vision of precision cardiology
  89. Liver-specific microRNA-122 as prognostic biomarker in patients with chronic systolic heart failure
  90. High-Density Lipoproteins Are the Main Carriers of PCSK9 in the Circulation
  91. FURIN Expression in Vascular Endothelial Cells Is Modulated by a Coronary Artery Disease–Associated Genetic Variant and Influences Monocyte Transendothelial Migration
  92. ApoCIII-Lp(a) complexes in conjunction with Lp(a)-OxPL predict rapid progression of aortic stenosis
  93. Preclinical development of a miR-132 inhibitor for heart failure treatment
  94. Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus: a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels
  95. Cartilage-like composition of keloid scar extracellular matrix suggests fibroblast mis-differentiation in disease
  96. Glycoproteomic Analysis of the Aortic Extracellular Matrix in Marfan Patients
  97. TIP 30 counteracts cardiac hypertrophy and failure by inhibiting translational elongation
  98. A Plasma Proteogenomic Signature for Fibromuscular Dysplasia
  99. Response by Schulte et al to Letter Regarding Article, “Comparative Analysis of Circulating Noncoding RNAs Versus Protein Biomarkers in the Detection of Myocardial Injury”
  100. Comparative Analysis of Circulating Noncoding RNAs Versus Protein Biomarkers in the Detection of Myocardial Injury
  101. Apolipoprotein Profiles in Very Preterm and Term‐Born Preschool Children
  102. Optogenetic Monitoring of the Glutathione Redox State in Engineered Human Myocardium
  103. Locally different proteome in aortas from patients with stenotic tricuspid and bicuspid aortic valves†
  104. Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology
  105. MicroRNAs: A New Understanding of Platelet Physiology and Pathology
  106. The Emerging Role of the ADAMTS Family in Vascular Diseases
  107. In Aptamers They Trust
  108. Inhibition of profibrotic microRNA-21 affects platelets and their releasate
  109. Hypoxia-induced epigenetic silencing of polo-like kinase 2 promotes fibrosis in atrial fibrillation
  110. Characterisation of circulating biomarkers before and after cardiac resynchronisation therapy and their role in predicting CRT response: the COVERT-HF study
  111. Higher spermidine intake is linked to lower mortality: a prospective population-based study
  112. Role of ADAMTS-5 in Aortic Dilatation and Extracellular Matrix Remodeling
  113. Extracellular Vesicle Crosstalk Between the Myocardium and Immune System Upon Infarction
  114. Metabolic changes in hypertrophic cardiomyopathies: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology
  115. Expanding the horizons of microRNA bioinformatics
  116. MicroRNA-24 and the Diabetic Heart
  117. Non-coding RNAs in vascular disease – from basic science to clinical applications: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology
  118. MicroRNA-21 and the Vulnerability of Atherosclerotic Plaques
  119. Downregulation of MicroRNA-126 Augments DNA Damage Response in Cigarette Smokers and Patients with Chronic Obstructive Pulmonary Disease
  120. Correction: Enzymatic lipid oxidation by eosinophils propagates coagulation, hemostasis, and thrombotic disease
  121. Cardiovascular Risk Beyond Low-Density Lipoprotein Cholesterol
  122. The innate immune system in chronic cardiomyopathy: a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC
  123. Extracellular Matrix Proteomics Reveals Interplay of Aggrecan and Aggrecanases in Vascular Remodeling of Stented Coronary Arteries
  124. Nox4 reprograms cardiac substrate metabolism via protein O-GlcNAcylation to enhance stress adaptation
  125. Comparison of MOLLI, shMOLLLI, and SASHA in discrimination between health and disease and relationship with histologically derived collagen volume fraction
  126. Plasma Proteomics for Epidemiology
  127. Cardiac myocyte miR-29 promotes pathological remodeling of the heart by activating Wnt signaling
  128. An integrative translational approach to study heart failure with preserved ejection fraction: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology
  129. Genetic Dissection of the Impact of miR-33a and miR-33b during the Progression of Atherosclerosis
  130. Very low-density lipoprotein associated apolipoproteins predict cardiovascular events and are lowered by inhibition of apoC-III
  131. CRISPR/Cas9 editing reveals novel mechanisms of clustered microRNA regulation and function
  132. What are the prospects of apolipoprotein profiling for cardiovascular disease?
  133. Cardiac myocyte β3-adrenergic receptors prevent myocardial fibrosis by modulating oxidant stress-dependent paracrine signaling
  134. Long Noncoding RNAs and Angiogenesis
  135. Proteomics of the epicardial fat secretome and its role in post-operative atrial fibrillation
  136. 195 Crispr/cas9 gene editing reveals novel tertiary constraints in clustered mirna processing
  137. Enzymatic lipid oxidation by eosinophils propagates coagulation, hemostasis, and thrombotic disease
  138. Association Between Vascular Cell Adhesion Molecule 1 and Atrial Fibrillation
  139. Epigenomic and transcriptomic approaches in the post-genomic era: path to novel targets for diagnosis and therapy of the ischaemic heart? Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart
  140. Mitochondria and ageing: role in heart, skeletal muscle and adipose tissue
  141. Glycoproteomics of the Extracellular Matrix: A Method for Intact Glycopeptide Analysis Using Mass Spectrometry
  142. Reply
  143. Extracellular matrix proteomics identifies molecular signature of symptomatic carotid plaques
  144. High-density lipoproteins in high resolution: Will proteomics solve the paradox for cardiovascular risk?
  145. Very-Low-Density Lipoprotein–Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III
  146. MicroRNA Biomarkers and Platelet Reactivity
  147. Premature senescence of endothelial cells upon chronic exposure to TNFα can be prevented by N-acetyl cysteine and plumericin
  148. Diabetes Mellitus–Induced Microvascular Destabilization in the Myocardium
  149. MicroRNAs in Cardiovascular Disease
  150. Circulating MicroRNA-122 Is Associated With the Risk of New-Onset Metabolic Syndrome and Type 2 Diabetes
  151. Potential and Caveats of Lipidomics for Cardiovascular Disease
  152. Cardioprotection and lifespan extension by the natural polyamine spermidine
  153. Native T1 and T2 mapping by CMR in lupus myocarditis: Disease recognition and response to treatment
  154. From basic mechanisms to clinical applications in heart protection, new players in cardiovascular diseases and cardiac theranostics: meeting report from the third international symposium on “New frontiers in cardiovascular research”
  155. Systems biology—opportunities and challenges: the application of proteomics to study the cardiovascular extracellular matrix
  156. Glycoproteomics Reveals Decorin Peptides With Anti-Myostatin Activity in Human Atrial Fibrillation
  157. Caveats of Untargeted Metabolomics for Biomarker Discovery ∗
  158. Identification of cyclins A1, E1 and vimentin as downstream targets of heme oxygenase-1 in vascular endothelial growth factor-mediated angiogenesis
  159. Proteomic and metabolomic changes driven by elevating myocardial creatine suggest novel metabolic feedback mechanisms
  160. Chronic miR‐29 antagonism promotes favorable plaque remodeling in atherosclerotic mice
  161. Loss of Biglycan Enhances Thrombin Generation in Apolipoprotein E -Deficient Mice
  162. Oxidant-induced Interprotein Disulfide Formation in Cardiac Protein DJ-1 Occurs via an Interaction with Peroxiredoxin 2
  163. Liver microRNAs: potential mediators and biomarkers for metabolic and cardiovascular disease?
  164. Extracellular matrix remodelling in response to venous hypertension: proteomics of human varicose veins
  165. Pharmacogenetics of Clopidogrel
  166. Vascular proteomics in metabolic and cardiovascular diseases
  167. “Young at heart”: Regenerative potential linked to immature cardiac phenotypes
  168. Guidelines for the functional annotation of microRNAs using the Gene Ontology
  169. Association of MicroRNAs and YRNAs With Platelet Function
  170. When Sweet Turns Salty
  171. Correlates of serum hepcidin levels and its association with cardiovascular disease in an elderly general population
  172. Meeting report from the 2nd International Symposium on New Frontiers in Cardiovascular Research. Protecting the cardiovascular system from ischemia: between bench and bedside
  173. Comparative analysis of statistical methods used for detecting differential expression in label-free mass spectrometry proteomics
  174. Inadequate hepcidin serum concentrations predict incident type 2 diabetes mellitus
  175. MicroRNA Biomarkers for Coronary Artery Disease?
  176. XBP 1-Deficiency Abrogates Neointimal Lesion of Injured Vessels Via Cross Talk With the PDGF Signaling
  177. Angiogenic microRNAs Linked to Incidence and Progression of Diabetic Retinopathy in Type 1 Diabetes
  178. Transformative Impact of Proteomics on Cardiovascular Health and Disease
  179. Sweet Dicer
  180. The cardiovascular gene annotation initiative: Impact on data analysis
  181. Asymmetric Dimethylarginine and Cardiovascular Risk: Systematic Review and Meta‐Analysis of 22 Prospective Studies
  182. Novel methodologies for biomarker discovery in atherosclerosis
  183. Proteomic analyses reveal that loss of TDP-43 affects RNA processing and intracellular transport
  184. Vascular Smooth Muscle Cell Calcification Is Mediated by Regulated Exosome Secretion
  185. ADAMTS-7 Inhibits Re-endothelialization of Injured Arteries and Promotes Vascular Remodeling Through Cleavage of Thrombospondin-1
  186. T1 values by conservative septal postprocessing approach are superior in relating to the interstitial myocardial fibrosis: findings from patients with severe aortic stenosis
  187. Cardiac-targeted NADPH oxidase 4 in the adaptive cardiac remodelling of the murine heart
  188. Affinity Proteomics for Phosphatase Interactions in Atrial Fibrillation∗
  189. Native T1 in Discrimination of Acute and Convalescent Stages in Patients With Clinical Diagnosis of Myocarditis
  190. Lipidomics
  191. Role of miR-195 in Aortic Aneurysmal Disease
  192. “Going Long”: Long Non-Coding RNAs as Biomarkers
  193. Discrimination and Net Reclassification of Cardiovascular Risk With Lipoprotein(a)
  194. Long‐term therapeutic silencing of miR‐33 increases circulating triglyceride levels and hepatic lipid accumulation in mice
  195. Redox State of Pentraxin 3 as a Novel Biomarker for Resolution of Inflammation and Survival in Sepsis
  196. Lipidomics Profiling and Risk of Cardiovascular Disease in the Prospective Population-Based Bruneck Study
  197. Cardiac fibroblast–derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy
  198. Tracing the Proteomic Fingerprint of the Diabetic Aorta?
  199. Targeting myocardial remodelling to develop novel therapies for heart failure
  200. Effects of Heparin on Temporal MicroRNA Profiles
  201. ESC Working Group on Myocardial Function Position Paper: how to study the right ventricle in experimental models
  202. Signature of circulating microRNAs in osteoarthritis
  203. LDL-receptor-deficient mice lacking microRNA-143/145 have less atherosclerosis
  204. Matrix Metalloproteinase-8 Promotes Vascular Smooth Muscle Cell Proliferation and Neointima Formation
  205. Phosphoregulation of the Titin-cap Protein Telethonin in Cardiac Myocytes
  206. Gene Network and Proteomic Analyses of Cardiac Responses to Pathological and Physiological Stress
  207. Impaired Antioxidant Defenses and Redox Signaling in GDM Fetal Endothelial Cells
  208. Histone Deacetylase 3 Unconventional Splicing Mediates Endothelial-to-mesenchymal Transition through Transforming Growth Factor β2
  209. Extracellular Matrix Secretion by Cardiac Fibroblasts
  210. Multidimensional separation prior to mass spectrometry: Getting closer to the bottom of the iceberg
  211. Oxidative stress in atherosclerosis: The role of microRNAs in arterial remodeling
  212. The Hypoxia-Inducible MicroRNA Cluster miR-199a∼214 Targets Myocardial PPARδ and Impairs Mitochondrial Fatty Acid Oxidation
  213. Macrophage MicroRNA-155 Promotes Cardiac Hypertrophy and Failure
  214. Heterogeneity in Neutrophil Microparticles Reveals Distinct Proteome and Functional Properties
  215. Proteomics and Metabolomics for Mechanistic Insights and Biomarker Discovery in Cardiovascular Disease
  216. Vascular Proteomics - The Forgotten Blood Vessels
  217. La proteómica y la metabolómica: los mecanismos de la enfermedad cardiovascular y el descubrimiento de biomarcadores
  218. MicroRNA biomarkers for failing hearts?
  219. Proteomics in aortic aneurysm - What have we learnt so far?
  220. Endothelial Seeding for Abdominal Aortic Aneurysms
  221. Glycoproteomic Analysis of the Secretome of Human Endothelial Cells
  222. Native T1 Mapping in Differentiation of Normal Myocardium From Diffuse Disease in Hypertrophic and Dilated Cardiomyopathy
  223. Circulating MicroRNAs as Novel Biomarkers for Platelet Activation
  224. From data gathering to systems medicine
  225. Effects of perhexiline-induced fuel switch on the cardiac proteome and metabolome
  226. MicroRNAs Within the Continuum of Postgenomics Biomarker Discovery
  227. Proteomic Identification of Matrix Metalloproteinase Substrates in the Human Vasculature
  228. Functional Role of Matrix Metalloproteinase-8 in Stem/Progenitor Cell Migration and Their Recruitment Into Atherosclerotic Lesions
  229. Impact of intravenous heparin on quantification of circulating microRNAs in patients with coronary artery disease
  230. A Sequential Extraction Methodology for Cardiac Extracellular Matrix Prior to Proteomics Analysis
  231. Cytochrome P4502S1: a novel monocyte/macrophage fatty acid epoxygenase in human atherosclerotic plaques
  232. Proteomics: from single molecules to biological pathways
  233. Oxidation-Specific Biomarkers, Prospective 15-Year Cardiovascular and Stroke Outcomes, and Net Reclassification of Cardiovascular Events
  234. Calpain inhibition stabilizes the platelet proteome and reactivity in diabetes
  235. Prospective Study on Circulating MicroRNAs and Risk of Myocardial Infarction
  236. Novel Role of ADAMTS-5 Protein in Proteoglycan Turnover and Lipoprotein Retention in Atherosclerosis
  237. European Perspectives
  238. The -omics era: Proteomics and lipidomics in vascular research
  239. Proteomics Analysis of Cardiac Extracellular Matrix Remodeling in a Porcine Model of Ischemia/Reperfusion Injury
  240. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs
  241. Review focus on the role of microRNA in cardiovascular biology and disease
  242. MicroRNAs in Vascular and Metabolic Disease
  243. Analytical challenges and technical limitations in assessing circulating MiRNAs
  244. Pathogenesis of Varicose Veins
  245. Method for Protein Subfractionation of Cardiovascular Tissues Before DIGE Analysis
  246. Proteomics of Atherosclerosis
  247. Terminal Differentiation, Advanced Organotypic Maturation, and Modeling of Hypertrophic Growth in Engineered Heart Tissue
  248. Profiling of circulating microRNAs: from single biomarkers to re-wired networks
  249. Chromobox Protein Homolog 3 Is Essential for Stem Cell Differentiation to Smooth Muscles In Vitro and in Embryonic Arteriogenesis
  250. Extracellular Matrix Composition and Remodeling in Human Abdominal Aortic Aneurysms: A Proteomics Approach
  251. Nitrosative protein oxidation is modulated during early endotoxemia
  252. Recent Highlights of Metabolomics in Cardiovascular Research
  253. Substrate Modifications Precede the Development of Atrial Fibrillation After Cardiac Surgery: A Proteomic Study
  254. Calcium Regulates Key Components of Vascular Smooth Muscle Cell–Derived Matrix Vesicles to Enhance Mineralization
  255. Comparative Lipidomics Profiling of Human Atherosclerotic Plaques
  256. From Bench to Bedside: What Physicians Need to Know About Endothelial Progenitor Cells
  257. Metabolic homeostasis is maintained in myocardial hibernation by adaptive changes in the transcriptome and proteome
  258. Adaptation to HIF-1 deficiency by upregulation of the AMP/ATP ratio and phosphofructokinase activation in hepatomas
  259. Proteomics
  260. Redox Regulation of Soluble Epoxide Hydrolase by 15-Deoxy-Δ-Prostaglandin J 2 Controls Coronary Hypoxic Vasodilation
  261. Cardiovascular stem cells revisited
  262. Proteomic characterization of human early pro-angiogenic cells
  263. Does Late Enhancement Imaging Decipher the Role of Myocardial Fibrosis in Hypertrophic Cardiomyopathy?
  264. Preoperative high-dose atorvastatin for prevention of atrial fibrillation after cardiac surgery: A randomized controlled trial
  265. Highlights from the 2010 BAS/BSCR spring meeting: New Frontiers in Cardiovascular Research
  266. Plasma MicroRNA Profiling Reveals Loss of Endothelial MiR-126 and Other MicroRNAs in Type 2 Diabetes
  267. Human cardiac and bone marrow stromal cells exhibit distinctive properties related to their origin
  268. Proteomics Characterization of Extracellular Space Components in the Human Aorta
  269. Short Communication: Asymmetric Dimethylarginine Impairs Angiogenic Progenitor Cell Function in Patients With Coronary Artery Disease Through a MicroRNA-21–Dependent Mechanism
  270. Comparative Proteomics Profiling Reveals Role of Smooth Muscle Progenitors in Extracellular Matrix Production
  271. Coupling Vascular and Myocardial Inflammatory Injury into a Common Phenotype of Cardiovascular Dysfunction: Systemic Inflammation and Aging – A Mini-Review
  272. Histone Deacetylase 7 Controls Endothelial Cell Growth Through Modulation of β-Catenin
  273. Phenotyping transgenic animals—An integrated readout of pathophysiology by combining proteomics and metabolomics with cardiovascular imaging
  274. Proteomics Analysis of the Cardiac Myofilament Subproteome Reveals Dynamic Alterations in Phosphatase Subunit Distribution
  275. Proteomic analysis of the secretome of human umbilical vein endothelial cells using a combination of free-flow electrophoresis and nanoflow LC-MS/MS
  276. Identification of Cardiac Myosin-binding Protein C as a Candidate Biomarker of Myocardial Infarction by Proteomics Analysis
  277. Proteomics, Metabolomics, and Immunomics on Microparticles Derived From Human Atherosclerotic Plaques
  278. Proteomic analysis reveals presence of platelet microparticles in endothelial progenitor cell cultures
  279. Asymmetric and symmetric dimethylarginines are of similar predictive value for cardiovascular risk in the general population
  280. Proteomics of acute coronary syndromes
  281. Proteomic and metabolomic analysis of cardioprotection: Interplay between protein kinase C epsilon and delta in regulating glucose metabolism of murine hearts
  282. Proteomics Identifies Thymidine Phosphorylase As a Key Regulator of the Angiogenic Potential of Colony-Forming Units and Endothelial Progenitor Cell Cultures
  283. Metabolomics
  284. Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study
  285. Letter by Metzler et al Regarding Article, “Intracoronary KAI-9803 as an Adjunct to Primary Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction”
  286. Cardiovascular Proteomics
  287. Proteomic analysis of secretory proteins and vesicles in vascular research
  288. Proteomic and Metabolomic Analysis of Smooth Muscle Cells Derived From the Arterial Media and Adventitial Progenitors of Apolipoprotein E–Deficient Mice
  289. The Paradox of Hypoxic and Oxidative Stress in Atherosclerosis⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Car...
  290. Combined Metabolomic and Proteomic Analysis of Human Atrial Fibrillation
  291. Integrated Membrane Protein Analysis of Mature and Embryonic Stem Cell-derived Smooth Muscle Cells Using a Novel Combination of CyDye/Biotin Labeling
  292. Oxidized Phospholipids, Lipoprotein(a), Lipoprotein-Associated Phospholipase A2 Activity, and 10-Year Cardiovascular Outcomes
  293. Protein Kinase D Selectively Targets Cardiac Troponin I and Regulates Myofilament Ca 2+ Sensitivity in Ventricular Myocytes
  294. Proteomics and Metabolomics Combined in Cardiovascular Research
  295. Proteomic analysis reveals higher demand for antioxidant protection in embryonic stem cell-derived smooth muscle cells
  296. The role of oxidant stress in angiotensin II-mediated contraction of human resistance arteries in the state of health and the presence of cardiovascular disease
  297. Proteomics-based Development of Biomarkers in Cardiovascular Disease
  298. Oxidized Low-Density Lipoprotein Autoantibodies, Chronic Infections, and Carotid Atherosclerosis in a Population-Based Study
  299. Oxidized Phospholipids Predict the Presence and Progression of Carotid and Femoral Atherosclerosis and Symptomatic Cardiovascular Disease
  300. Association of Serum-Soluble Heat Shock Protein 60 With Carotid Atherosclerosis
  301. Metabolic profiling of hypoxia-inducible factor-1β-deficient and wild type Hepa-1 cells: effects of hypoxia measured by 1H magnetic resonance spectroscopy
  302. Proteomic dataset of Sca-1+ progenitor cells
  303. Proteomic dataset of mouse aortic smooth muscle cells
  304. Proteomic and Metabolomic Analyses of Atherosclerotic Vessels From Apolipoprotein E-Deficient Mice Reveal Alterations in Inflammation, Oxidative Stress, and Energy Metabolism
  305. Role of oxidative stress in angiotensin-II mediated contraction of human conduit arteries in patients with cardiovascular disease
  306. Vascular proteomics: Linking proteomic and metabolomic changes
  307. Pitfalls of Proteomics
  308. Ischemic preconditioning exaggerates cardiac damage in PKC-δ null mice
  309. Loss of PKC-δ alters cardiac metabolism
  310. Proteomic and Metabolomic Analysis of Vascular Smooth Muscle Cells
  311. Cross-Reactive B-Cell Epitopes of Microbial and Human Heat Shock Protein 60/65 in Atherosclerosis
  312. Mechanical Stretch-Induced Apoptosis in Smooth Muscle Cells Is Mediated by β 1 -Integrin Signaling Pathways
  313. Increased Risk of Atherosclerosis Is Confined to CagA-Positive Helicobacter pylori Strains
  314. Both Donor and Recipient Origins of Smooth Muscle Cells in Vein Graft Atherosclerotic Lesions
  315. Smooth Muscle Cells in Transplant Atherosclerotic Lesions Are Originated From Recipients, but Not Bone Marrow Progenitor Cells
  316. Active and Passive Smoking, Chronic Infections, and the Risk of Carotid Atherosclerosis
  317. Mechanical Stress‐induced DNA damage and rac‐p38MAPK Signal Pathways Mediate p53‐dependent Apoptosis in Vascular Smooth Muscle Cells
  318. Loss of p53 Accelerates Neointimal Lesions of Vein Bypass Grafts in Mice
  319. Exacerbated vein graft arteriosclerosis in protein kinase Cδ–null mice
  320. Smooth muscle cell apoptosis in arteriosclerosis
  321. Chronic Infections and the Risk of Carotid Atherosclerosis
  322. Infections, Immunity, and Atherosclerosis
  323. Rapid Development of Vein Graft Atheroma in ApoE-Deficient Mice
  324. Serum Soluble Heat Shock Protein 60 Is Elevated in Subjects With Atherosclerosis in a General Population
  325. Reduced Neointima Hyperplasia of Vein Bypass Grafts in Intercellular Adhesion Molecule-1–Deficient Mice
  326. Association of Serum Antibodies to Heat-Shock Protein 65 With Carotid Atherosclerosis
  327. Cyclic Strain Stress-induced Mitogen-activated Protein Kinase (MAPK) Phosphatase 1 Expression in Vascular Smooth Muscle Cells Is Regulated by Ras/Rac-MAPK Pathways
  328. Inhibition of Arteriosclerosis by T-Cell Depletion in Normocholesterolemic Rabbits Immunized With Heat Shock Protein 65
  329. Endothelial Cytotoxicity Mediated by Serum Antibodies to Heat Shock Proteins of Escherichia coli and Chlamydia pneumoniae
  330. Macrophage-lysis mediated by autoantibodies to heat shock protein 65/60